Cargando…
eP187: Decentralization of clinical trials in the era of COVID-19: Implications for rare disease trials
Autores principales: | Manjrekar, Kriti, Freeman, Mary, Hedstrom, Karli, Fierro, Luca, Naik, Hetanshi, Diaz, George, Balwani, Manisha, Ganesh, Jaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935066/ http://dx.doi.org/10.1016/j.gim.2022.01.223 |
Ejemplares similares
-
The N370S/R496H genotype in type 1 Gaucher disease – Natural history and implications for pre symptomatic diagnosis and counseling
por: Zeid, Natasha, et al.
Publicado: (2020) -
Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021) -
Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York
por: Fierro, Luca, et al.
Publicado: (2021) -
The decay of $^{187}$Pt: comparison of the levels of $^{187}$Ir
por: Sébille-Schück, C, et al.
Publicado: (1973) -
First experience of a fully decentralized clinical trial: The dawn of a new era in oncology
por: Taniguchi, Hiroya, et al.
Publicado: (2023)